Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PPAR receptors: recent data].

H Vidal1

  • 1INSERM U449/INRA U1235, Faculté de Médecine Laënnec, Université Claude-Bernard, F-69372 Lyon Cedex 08, France. vidal@laennec.univ-lyon1.fr

Annales D'Endocrinologie
|June 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut commensal Bacteroides faecichinchillae, a potential novel candidate of next-generation probiotics targeting type 2 diabetes.

Beneficial microbes·2026
Same author

Reduced fibre size, capillary supply and mitochondrial activity in constitutional thinness' skeletal muscle.

Acta physiologica (Oxford, England)·2018
Same author

High expression of CPT1b in skeletal muscle in metabolically healthy older subjects.

Diabetes & metabolism·2018
Same author

WY-14643 and 9-cis-retinoic acid induce IRS-2/PI 3-kinase signalling pathway and increase glucose transport in human skeletal muscle cells: differential effect in myotubes from healthy subjects and Type 2 diabetic patients.

Diabetologia·2017
Same author

Salivary composition in obese vs normal-weight subjects: towards a role in postprandial lipid metabolism?

International journal of obesity (2005)·2015
Same author

Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients.

Thrombosis and haemostasis·2015
Same journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
See all related articles

Peroxisome Proliferator-Activated Receptors (PPARs) are key regulators of lipid and glucose metabolism. Activating PPARbeta/delta in skeletal muscle may offer a new treatment for insulin resistance and metabolic syndrome.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolic Research

Background:

  • Nuclear receptors Peroxisome Proliferator-Activated Receptors (PPARs) form heterodimers with RXR to regulate gene transcription.
  • PPARs are activated by natural or synthetic ligands, influencing lipid metabolism, adipocyte differentiation, and glucose homeostasis.
  • Three PPAR subtypes (PPARalpha, PPARbeta/delta, PPARgamma) exist, with PPARgamma having two human isoforms (PPARgamma1, PPARgamma2).

Purpose of the Study:

  • To review current data on PPAR receptor subtypes: expression, biological functions, and ligands.
  • To explore the role of PPARs in lipid and glucose metabolism and their clinical applications.
  • To discuss the potential of PPARbeta/delta activation in skeletal muscle for treating insulin resistance and metabolic syndrome.

Main Methods:

Related Experiment Videos

  • Literature review of existing data on PPAR receptor subtypes.
  • Summary of information on natural and synthetic PPAR ligands.
  • Discussion of experimental data regarding PPARbeta/delta activation in skeletal muscle.

Main Results:

  • PPARs are crucial modulators of lipid and glucose metabolism.
  • Synthetic PPAR agonists are used clinically as hypolipidaemic (fibrates) and antidiabetic (thiazolidinediones) agents.
  • Impaired lipid metabolism in insulin-resistant skeletal muscles suggests a role for fatty acids in pathophysiology.

Conclusions:

  • PPAR receptor subtypes have distinct pharmacological profiles and significant roles in metabolic regulation.
  • PPARalpha agonists (fibrates) treat hyperlipidemia, and PPARgamma agonists (glitazones) manage diabetes.
  • Activating PPARbeta/delta in skeletal muscle presents a promising therapeutic strategy for insulin resistance and metabolic syndrome.